Michael Hughes1, Voon H Ong2, Marina E Anderson3, Frances Hall4, Pia Moinzadeh5, Bridget Griffiths6, Eileen Baildam7, Christopher P Denton2, Ariane L Herrick8. 1. Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, michael.hughes-6@postgrad.manchester.ac.uk. 2. Centre for Rheumatology, Royal Free Hospital, London. 3. Institute of Ageing and Chronic Disease, Faculty of Health & Life Sciences, University of Liverpool. 4. Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 5. Department for Dermatology and Venereology, University of Cologne, Cologne, Germany. 6. Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne and. 7. Department of Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, UK. 8. Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester.
Abstract
OBJECTIVE: Digital vasculopathy (comprising RP, digital ulceration and critical digital ischaemia) is responsible for much of the pain and disability experienced by patients with SSc. However, there is a limited evidence base to guide clinicians in the management of SSc-related digital vasculopathy. Our aim was to produce recommendations that would be helpful for clinicians, especially for those managing patients outside specialist centres. METHODS: The UK Scleroderma Study Group set up several working groups to develop a number of consensus best practice pathways for the management of SSc-specific complications, including digital vasculopathy. RESULTS: This overview presents the background and best practice consensus pathways for SSc-related RP, digital ulceration and critical ischaemia. Examples of drug therapies, including doses, are suggested in order to inform prescribing practice. CONCLUSION: A number of treatment algorithms are provided that are intended to provide the clinician with accessible reference tools for use in daily management.
OBJECTIVE:Digital vasculopathy (comprising RP, digital ulceration and critical digital ischaemia) is responsible for much of the pain and disability experienced by patients with SSc. However, there is a limited evidence base to guide clinicians in the management of SSc-related digital vasculopathy. Our aim was to produce recommendations that would be helpful for clinicians, especially for those managing patients outside specialist centres. METHODS: The UK Scleroderma Study Group set up several working groups to develop a number of consensus best practice pathways for the management of SSc-specific complications, including digital vasculopathy. RESULTS: This overview presents the background and best practice consensus pathways for SSc-related RP, digital ulceration and critical ischaemia. Examples of drug therapies, including doses, are suggested in order to inform prescribing practice. CONCLUSION: A number of treatment algorithms are provided that are intended to provide the clinician with accessible reference tools for use in daily management.
Authors: Christopher A Mecoli; Ami A Shah; Francesco Boin; Fredrick M Wigley; Laura K Hummers Journal: Clin Rheumatol Date: 2018-05-26 Impact factor: 2.980
Authors: Michael Hughes; Begonya Alcacer-Pitarch; Ana Maria Gheorghiu; Emanuela Praino; Robert David Sandler; Yonit Tavor; Cosimo Bruni; Marco Matucci-Cerinic Journal: Clin Rheumatol Date: 2020-01-18 Impact factor: 2.980
Authors: Elizabeth Reilly; Randa Alshakh; Celia Beynon; Matthew Cates; Dhivya Das; Shuja Majeed; Ahsan Memon; Patrick O'Beirn; James Ritchie; John D Pauling Journal: Clin Med (Lond) Date: 2020-05 Impact factor: 2.659